RxDoctor Payments Data

Anish Patel, PA

Physician Assistant · Glendale, AZNPI 1861901712

Payments from drug & device makers

$6,385in general payments, 2019–2025

Across 283 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$757
  • Neurocrine Biosciences, Inc.$595
  • Teva Pharmaceuticals USA, Inc.$411
  • Alkermes, Inc.$196
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,28898%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,385 in reported general payments places this provider in the 90th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$52,383
Medicare patients
58
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl16$25,409
Lurasidone Hcl15$18,865
Buspirone Hcl196$3,408
Bupropion XlBupropion Hcl176$3,064
Quetiapine Fumarate191$2,418
Sertraline Hcl266$1,933
Aripiprazole140$1,735
Alprazolam179$1,390
Olanzapine104$1,266
Lamotrigine70$1,130
Trazodone Hcl224$1,107
Hydroxyzine Hcl81$1,011
Mirtazapine68$950
Duloxetine Hcl40$940
Escitalopram Oxalate125$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,533$25,40916 claims
Almatica Pharma LLCSertraline Hcl$132$1,933266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →